Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection

被引：14
作者：
Brancaccio, Giuseppina [1 ]
Gaeta, Giovanni B. [2 ]
机构：
[1] Univ Padua, Dept Mol Med, Infect Dis, Padua, Italy
[2] Campania Univ, Dept Mental & Phys Hlth, Infect Dis, Naples, Italy
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2019年 / 54卷 / 06期
关键词：
Hepatitis delta virus; Peg-IFN; Prenylation inhibitor; Entry inhibitor; HBsAg release blocker; IFN-lambda; PEGYLATED INTERFERON ALPHA-2A; PEG-INTERFERON; VANISHING DISEASE; CLINICAL-TRIAL; MYRCLUDEX B; OPEN-LABEL; EFFICACY; THERAPY; INFECTION; RNA;
D O I：
10.1016/j.ijantimicag.2019.09.012
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
An estimated 20-40 million individuals worldwide are infected with hepatitis delta virus (HDV), mostly with rapidly evolving liver disease. Therapy of chronic HDV infection remains an unmet need. To date, only interferon (IFN)-based therapy is recommended for HDV infection and response rates are unsatisfactory; in addition, many patients are intolerant to or ineligible for IFN treatment. In recent years, innovative approaches have been in development, including the following: targeting virus entry into hepatocytes; inhibition of the host enzyme farnesyltransferase by prenylation inhibitors, leading to inhibition of complete virion formation and release; blockade of hepatitis B surface antigen (HBsAg) secretion, inhibiting virus release; and IFN-lambda, which causes fewer adverse effects than IFN-alfa. Clinical trials are ongoing with encouraging preliminary results. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码：697 / 701
页数：5
相关论文
共 64 条
[1]   Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial [J].
Abbas, Zaigham ;
Memon, Mohammad Sadik ;
Umer, Muhammad Amir ;
Abbas, Minaam ;
Shazi, Lubna .
WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (14) :625-631
[2]   Interferon alpha for chronic hepatitis D [J].
Abbas, Zaigham ;
Khan, Muhammad Arsalan ;
Salih, Mohammad ;
Jafri, Wasim .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12)
[3]   An update on HDV: virology, pathogenesis and treatment [J].
Alvarado-Mora, Monica V. ;
Locarnini, Stephen ;
Rizzetto, Mario ;
Rebello Pinho, Joao R. .
ANTIVIRAL THERAPY, 2013, 18 (03) :541-548
[4]  
Bazinet M, 2018, LANCET GASTROENTEROL, V3, pE1
[5]   Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial [J].
Bazinet, Michel ;
Pantea, Victor ;
Cebotarescu, Valentin ;
Cojuhari, Lilia ;
Jimbei, Pavlina ;
Albrecht, Jeffrey ;
Schmid, Peter ;
Le Gal, Frederic ;
Gordien, Emmanuel ;
Krawczyk, Adalbert ;
Mijocevic, Hrvoje ;
Karimzadeh, Hadi ;
Roggendorf, Michael ;
Vaillant, Andrew .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12) :877-889
[6]   Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study [J].
Bogomolov, Pavel ;
Alexandrov, Alexander ;
Voronkova, Natalia ;
Macievich, Maria ;
Kokina, Ksenia ;
Petrachenkova, Maria ;
Lehr, Thorsten ;
Lempp, Florian A. ;
Wedemeyer, Heiner ;
Haag, Mathias ;
Schwab, Matthias ;
Haefeli, Walter E. ;
Blank, Antje ;
Urban, Stephan .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :490-498
[7]   In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus [J].
Bordier, BB ;
Ohkanda, J ;
Liu, P ;
Lee, SY ;
Salazar, FH ;
Marion, PL ;
Ohashi, K ;
Meuse, L ;
Kay, MA ;
Casey, JL ;
Sebti, SM ;
Hamilton, AD ;
Glenn, JS .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :407-414
[8]   A prenylation inhibitor prevents production of infectious hepatitis delta virus particles [J].
Bordier, BB ;
Marion, PL ;
Ohashi, K ;
Kay, MA ;
Greenberg, HB ;
Casey, JL ;
Glenn, JS .
JOURNAL OF VIROLOGY, 2002, 76 (20) :10465-10472
[9]   Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir [J].
Brancaccio, Giuseppina ;
Fasano, Massimo ;
Grossi, Adriano ;
Santantonio, Teresa Antonia ;
Gaeta, Giovanni B. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (08) :1071-1076
[10]   The present profile of chronic hepatitis B virus infection highlights future challenges An analysis of the Multicenter Italian MASTER-B cohort [J].
Brancaccio, Giuseppina ;
Nardi, Alessandra ;
Madonia, Salvatore ;
Fasano, Massimo ;
Verucchi, Gabriella ;
Massari, Marco ;
Maimone, Sergio ;
Contini, Carlo ;
Levantesi, Fabio ;
Alfieri, Arianna ;
Gavrila, Caius ;
Andreone, Pietro ;
Milella, Michele ;
Gaeta, Giovanni B. .
DIGESTIVE AND LIVER DISEASE, 2019, 51 (03) :438-442
1234567